TAM Global Appoints One of the World's Leading Tumor Immunologists to Oversee Scientific Strategy Across Its Expanding Healthcare Platform NASHVILLE, Tenn., June 23, 2025 /PRNewswire/ -- TAM Global, the disruptive force in translational and regenerative medicine, proudly announces that Dr. Francesco Marincola, MD, FACS, has joined the organization as Chief Scientific Officer. In this role, Dr. Marincola will serve as CSO of all companies under the TAM Global umbrella, including TAM Center, TAM C

DETROIT , June 23, 2025 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute, cancer centers, and other organizations across the nation recognize June as National Cancer Survivor Month. A cancer survivor is anyone with a history of cancer from the time they were diagnosed through the remainder of their life. June is a time to celebrate and honor the millions who have beaten cancer and encourage those who are currently undergoing treatment. Cancer Facts and Figures Continue Reading Karmanos

OR YEHUDA, Israel, June 23, 2025 /PRNewswire/ -- EcoPhage, a leader in the development and commercialization of sustainable phage-based biopesticides for bacterial plant diseases, expecting its first U.S. EPA approval, is pleased to announce the appointment of Mr. José Alfredo García, to its Board of Directors. With extensive experience in building and scaling global agribusiness platforms, García joins at a pivotal time as the company prepares for commercial rollout in key markets Mr. García h

MEQUON, Wis., June 23, 2025 /PRNewswire/ -- Milwaukee Capital Partners LLC, Milwaukee, WI (MCP) is pleased to announce the acquisition of MPP Group LLC., Mequon, WI (MPP), effective May 1, 2025. Joining MCP on the acquisition of MPP was an investment by Concordia University Ventures (CU Ventures) led by Daniel Sem. MPP Group will maintain its company headquarters in the Mequon Technical Park, a rapidly growing area of scientific and soft manufacturing excellence as they advance their investment

小细胞肺癌新药ZL-1310，疾病控制率高达93%；HER2阳性胃癌有望用上新一代双抗药；淋巴瘤治疗方案升级，无进展时间延长3倍！；中国团队：肺癌脑转移患者，鞘注化疗让超一半人活过1年；想了解基因检测、免费临床试药机会？欢迎私信癌度。 #肺癌 #胃癌 #淋巴瘤 #抗癌新药 #癌症治疗进展 #癌度快报 #肿瘤资讯 #临床试验 #癌症希望

2025年6月23日，美国旧金山和中国苏州——信达生物制药集团（香港联交所股票代码：01801），一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布：第三代表皮生长因子受体酪氨酸激酶（EGFR）抑制剂（TKI）利厄替尼片（奥壹新®）一线治疗具有EGFR外显子19缺失或外显子21（L858R）置换突变的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的III期临床研究结果在国际顶级医学期刊《柳叶刀·呼吸病学》全文在线发表。此前，信达生物与奥赛康药业就利厄替尼片在中国已达成独家商业化合作。此次发表的临床研究由中国医学科学院肿瘤医院石远凯教授牵头，共有56家中国医院参与，是一项多中心、随机、双盲、阳性对照的III期临床研究，旨在比较利厄替尼与吉非替尼用于一线治疗具有EGFR敏感突变的局部晚期或转移性NSCLC患者的疗效和安全性。符合条件的患者年龄在18周岁及以上，经组织学确诊为局部晚期或转移性非小细胞肺癌，且确认存在EGFR外显子19缺失或外显子21（L858R）置换突变。患者按1:1随机分组，试验组接受口服利厄替尼（每天二次，每次8

Research indicates potential for new wave of breakthroughs in maintaining lean mass for patients taking GLP-1-based medications CHICAGO, June 23, 2025 /PRNewswire/ -- Findings from two groundbreaking studies highlight potential pharmacological and biosensor solutions for muscle mass preservation in patients undergoing obesity treatment therapy. Results from the BELIEVE study of bimagrumab and semaglutide combination therapy and a study of a novel continuous protein sensor for sarcopenia manageme

JERSEY CITY, N.J., June 23, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the three-year launch anniversary of RADICAVA ORS® (edaravone) in the U.S. Since its availability in June 2022, RADICAVA ORS has been used to treat over 13,519 people living with amyotrophic lateral sclerosis (ALS).1 "Reflecting on the past three years since the approval of RADICAVA ORS, I am encouraged by the progress we have made in providing a treatment for the thousands living with

BIRMINGHAM, Ala. and BEIJING, June 23, 2025 /PRNewswire/ -- Archimedes Vascular, Inc., a pre-clinical stage medical device company developing an implant for the treatment of severe hypertension announced a $2.2 million Series A financing led by Sherpa Healthcare Partners. In conjunction with the financing, also announced the appointment of veteran medical device executive, Raymond W. Cohen to serve as chairman of its board of directors. "We are grateful to Sherpa and Ray for recognizing the pote

New construct represents a strategic expansion of the company's leading hip portfolio GAINESVILLE, Fla., June 23, 2025 /PRNewswire/ -- Exactech, a global medical device technology leader, announced the first surgery using the new Alteon® Short Tapered Wedge Hip Stem. The procedure was performed by Mark Schinsky, MD, with The American Hip Institute & Orthopedic Specialists in Chicago. Continue Reading Exactech’s Alteon® Short Tapered Wedge Hip Stem is a next-generation solution designed to fit a